Express Pharma
Home  »  COVID-19 Updates  »  Novavax and Canada reach agreement in principle for 76 mn doses of COVID-19 vaccine

Novavax and Canada reach agreement in principle for 76 mn doses of COVID-19 vaccine

NVX-CoV2373 is currently in multiple Phase 2 clinical trials

0 200
Read Article

Novavax has announced that it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine.

“We are pleased to work with the Canadian government on supply of our COVID-19 vaccine, an essential step to ensure broad access of our vaccine candidate,” said Stanley C Erck, President and Chief Executive Officer of Novavax.

“We are pleased to announce this agreement with Novavax, which will give Canadians access to a promising COVID-19 vaccine candidate. This is an important step in our government’s efforts to secure a vaccine to keep Canadians safe and healthy, as the global pandemic evolves,” said Anita Anand, Minister of Public Services and Procurement, Government of Canada.

Novavax and Canada expect to finalise an advance purchase agreement under which Novavax will supply doses of NVX-CoV2373 to Canada beginning as early as the second quarter of 2021. This purchase arrangement will be subject to licensure of the Novavax vaccine by Health Canada.

NVX-CoV2373 is currently in multiple Phase 2 clinical trials. The Phase 2 portion of the Phase 1/2 clinical trial to evaluate the safety and immunogenicity of NVX-CoV2373 began in August in the US and Australia, and expands on the age range of the Phase 1 portion by including older adults 60-84 years of age as approximately 50 percent of the trial population. Secondary objectives include preliminary evaluation of efficacy. In addition, a Phase 2b clinical trial to assess efficacy began in South Africa in August.

Leave A Reply

Your email address will not be published.